linjc16/ctgov huggingface dataset:
Clindamycin-trimethoprim/Sulfamethoxazole for PCP After Solid Organ Transplantation Population.

Study Overview
=================
Brief Summary
-----------------
PCP is one of the common opportunistic infections in patients with HIV and non-HIV-associated immunodeficiency.With the increasing number of solid organ transplantation, how to effectively treat severe PCP after solid organ transplantation has become an urgent problem to be solved.In general, Atovaquone, Dapsone, and Clindamycin-primaquine can be used as second-line alternatives when TMP-SMX fails to treat HIV-PCP. Therefore, the objective of this study is to preliminarily investigate the safety and efficacy of low-dose TMP-SMX combined with clindamycin (CT regimen) for the treatment of severe PCP after solid organ transplantation.

Detailed Description
-----------------
PCP is one of the common opportunistic infections in patients with HIV and non-HIV-associated immunodeficiency.With the increasing number of solid organ transplantation, how to effectively treat severe PCP after solid organ transplantation has become an urgent problem to be solved.In general, Atovaquone, Dapsone, and Clindamycin-primaquine can be used as second-line alternatives when TMP-SMX fails to treat HIV-PCP. More and more studies suggest that clindamycin-based alternatives play an increasingly important role in treating of PCP. Therefore, the objective of this study is to preliminarily investigate the safety and efficacy of low-dose TMP-SMX combined with clindamycin (CT regimen) for the treatment of severe PCP after solid organ transplantation.

Official Title
-----------------
Clindamycin - Trimethoprim/Sulfamethoxazole for Pneumocystis Jiroveci Pneumonia After Solid Organ Transplantation Population (CTSTOP)

Conditions
-----------------
Pneumocystis Jirovecii Pneumonia, Solid Organ Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PJP after solid organ transplantation. Exclusion Criteria: renal failure,heart failure,tumor recurrence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oxygenation index | PaO2/FiO2 | through study completion, an average of 20 days | 
| length of ICU stay | Total length of stay in ICU | through study completion, an average of 20 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse reactions of drugs | Rash，Anorexia，Decreased white blood cell count，Anemia，Decreased platelet count，Increased TB，Increased creatinine，Hyperkalemia | through study completion, an average of 20 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TMP-SMX, clindamycin, oxygenation index, adverse reactions
The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that ten sessions of repetitive transcranial magnetic stimulation yield ability to upregulate the function of primary motor cortex and prefrontal cortex that play key roles in motor and frontal memory processing.

Detailed Description
-----------------
Excitatory (>3Hz) rTMS could facilitate the brain cortex and neuroplasticity that benefits motor control and working memory when the coil is applied over primary motor cortex or dorsolateral prefrontal gyrus.

Official Title
-----------------
The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory in Stroke, Parkinson, and Elderly Patients

Conditions
-----------------
Central Nervous System Diseases

Intervention / Treatment
-----------------
* Device: Functional near infrared spectroscopy
* Device: rTMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ischemic or hemorrhagic cerebrovascular lesion, Parkinson's disease Exclusion Criteria: Seizure With metal implantation Dementia or severe cognitive impairment

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High frequency rTMS plus fNIRS<br>rTMS with neuroimage assessment of functional near infrared spectroscopy | Device: Functional near infrared spectroscopy<br>* Using high-sensitivity infrared to detect the active brain areas<br>* Other names: fNIRS;Device: rTMS<br>* To modulate brain cortex<br>|
| Sham Comparator: Sham rTMS<br>Sham stimulation | Device: rTMS<br>* To modulate brain cortex<br>|
| Experimental: High frequency rTMS<br>High frequency rTMS to modulate brain areas | Device: rTMS<br>* To modulate brain cortex<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Repeatable Battery for the Assessment of Neuropsychological Status | Test cognition including memory, attention, language... | Up to 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Montreal Cognitive Assessment | Test cognition including memory, attention, and language. | Up to 12 weeks | 
| Change of Fugl-Meyer Assessment , Wolf Motor Function Test | Test upper limb motor function. | Up to 12 weeks |
Survival Outcomes of Uterine Cervical Malignancies in Chinese Population

Study Overview
=================
Brief Summary
-----------------
This study aims to determine survival outcomes (overall survival and progression-free survival) of primary malignancies of uterine cervix in China and relevant risk factors in a prospective cohort study.

Official Title
-----------------
Survival Outcomes of Uterine Cervical Malignancies in Chinese Population

Conditions
-----------------
Uterine Cervical Neoplasms, Survival

Intervention / Treatment
-----------------
* Other: Follow-up for death and recurrence of patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary malignancies of uterine cervix. Exclusion Criteria: Secondary malignancies of uternie cervix.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Duration from diagnosis to recurrence | 5 years | 
| Progression-free survival | Duration from last treatment after remission to recurrence | 5 years |
Systemic Lupus Erythematosus in Gullah Health

Study Overview
=================
Brief Summary
-----------------
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.

Official Title
-----------------
Systemic Lupus Erythematosus in Gullah Health

Conditions
-----------------
Systemic Lupus Erythematosus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 2 years and above; Self-identified as African-American Gullah from the Sea Island region of South Carolina; Have had at least 4 of the 11 diagnostic criteria for SLE as designated by the American College of Rheumatology (ACR), be a relative of a known SLE patient, or be an unrelated healthy Gullah control; Ability to speak and understand English; Ability and willingness to give informed consent Exclusion Criteria: Race defined by participant as other than Black or African-American; Being a prisoner, mentally ill patient, or institutionalized individual; Unwilling or unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with SLE | |
| 2<br>Related unaffected controls | |
| 3<br>Unrelated unaffected controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
African Americans
The Factors That Inhibit Women Who Smoke to do Pap Smear Test

Study Overview
=================
Brief Summary
-----------------
Discovery of factors affect the decision of the woman to perform or not to perform a Pap test.Participate in the study 100 women who smoke. Age range 18-60

Detailed Description
-----------------
The data collected through questionnaires to the women. Data analysis will be performed by using Statistical Analysis- SPSS

Official Title
-----------------
To Find Factors That Inhibit Women Who Smoke to do Pap Smear Test

Conditions
-----------------
Smoking Woman, 18-60 Years Old

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: smoking woman 18-60 years old Exclusion Criteria: not smoking Not want to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| smoking woman 18-60 years old<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Why does not a woman who smokes do Pap test | Discovery of factors affect the decision of the woman to perform or not to perform a Pap test. Participate in the study 100 women who smoke. Age range 18-60 The data collected through questionnaires to the women. Data analysis will be performed by using Statistical Analysis- SPSS | 2 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smoking woman
Ketohexokinase Isoforms in Endometrial Cancer.

Study Overview
=================
Brief Summary
-----------------
Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.

Official Title
-----------------
Prognostic Evaluations of Ketohexokinase Isoforms in Endometrial Cancer

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: ketohexokinase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >20 years Women with endometrial cancer who are about to be admitted to hospital for gynecological staging. Women who have undergone gynecological staging surgery for endometrial cancer in the past. Exclusion Criteria: Women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The role of ketohexokinase isoforms in the overall survival of endometrial cancer. | Cox proportional hazard regression to evaluate the role of ketohexokinase isoforms in the overall survival of endometrial cancer. | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of ketohexokinase isoforms with the other prognostic risk factors | Correlation of ketohexokinase isoforms with deep myometrial invasion, tumor grade, lymph node metastasis, FIGO stage, tumor size, progression-free survival, etc. | 5 years |
Informed Consent in Endoscopy: Read, Understood or Merely Signed?

Study Overview
=================
Brief Summary
-----------------
Informed consent form is a legal document that, ethically, should be obtained before any endoscopic procedure is performed. The main purpose of this research study is to assess the readability, comprehensibility and applicability of the new informed consent proposed by the Portuguese Society of Digestive Endoscopy as a way to standardize the information provided to patients prior to endoscopic exams.

Official Title
-----------------
Informed Consent in Endoscopy: Read, Understood or Merely Signed?

Conditions
-----------------
Informed Consent, Gastrointestinal Endoscopy

Intervention / Treatment
-----------------
* Behavioral: Reading of informed consent form


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients able to autonomously give informed consent Patients refered to elective endoscopic procedures (upper digestive endoscopy and/or colonoscopy) without deep sedation. Exclusion Criteria: Patients refered to urgent endoscopic procedures Patients refered for endoscopic procedures with deep sedation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Reading of informed consent form|Patients that adequately read informed consent forms|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessing the percentage of patients who adequate read informed consent forms | Assess if patients adequately read informed consent forms - adequate reading was defined by checking all of the following: signing of informed consent form; fulfilment of a questionnaire regarding medical history and drugs; underlining a small sentence added to the orignial version of informed consent form. Patients not meeting all the defined criteria were considered not to have adequately read the informed consent. | 12 months |
A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet

Study Overview
=================
Brief Summary
-----------------
The primary aim of this trial is to evaluate the efficacy of the ALK house dust mite tablet given once daily compared to a placebo tablet in the treatment of house dut mite allergic rhinits. Additionally the secondary objective of the trial is to evaluate the safety and tolarability of the ALK house dust mite tablet. Immunotherapy has been shown to provide therapeutic benefits to subjects with house dust mite induced allergy. This trial is planned to investigate if clinically relevant improvements in rhinitis symptoms and with less use of symptomatic medication can be obtained in subjects with a history of poor didease control despite of use of symptomatic medications.

Conditions
-----------------
House Dust Mite Allergy

Intervention / Treatment
-----------------
* Biological: AIT Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A history of house dust mite allergy Use of symptomatice medication for treatment of house dust mite allergy Positive skin prick test to mites Positive specific IgE Exclusion Criteria: History of uncontrolled asthma Overlapping symptomatice allergies Previous treatment with immunotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ALK house dust mite tablet 6 DU<br> | Biological: AIT Tablet<br>* 1 tablet per day in 12 months<br>|
| Experimental: ALK house dust mite tablet 12 DU<br> | Biological: AIT Tablet<br>* 1 tablet per day in 12 months<br>|
| Placebo Comparator: Placebo<br> | Biological: AIT Tablet<br>* 1 tablet per day in 12 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of allergy symptoms and use of symptomatic medication | Comparing the daily recording of symptoms and use of symptomatic medication during the last period of the trial between the actively treated patients and the placebo treated. | 1 year with treatment |
Multi-center Imaging Genetics Studies in China

Study Overview
=================
Brief Summary
-----------------
To study the impact of genetic and environmental factors on high-level cognition associated neural circuits among healthy young Chinese Han subjects.

Detailed Description
-----------------
The investigators plan to collect behavioral assessment and environmental factors data,peripheral blood sample, MRI brain images in more than 10,000 healthy young Chinese Han individuals in order to build the pathway from gene to high-level cognitive phenotypes.

Official Title
-----------------
Multi-center Imaging Genetics Studies in China

Conditions
-----------------
Alzheimer Disease, Schizophrenia, Major Depressive Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18-30 Chinese Han right-handed without history of neuropsychiatric disease no substance addiction smoking Exclusion Criteria: younger or elder than 18-30 year-old other ethnics with history of neuropsychiatric disease with history of neuropsychiatric disease among first,second and third degree relatives

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy young subjects<br>Healthy young Chinese Han subjects aged 18-30 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain structure and function measured by MRI scans | The participants will receive non-interventional multi-modal MRI scans, such as 3D-T1WI, DTI, DKI, ASL, REST-fmri, then the investigators can acquire the brain volume in region of interest, such as bilateral hippocampus. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Childhood adversities as assessed by Childhood Trauma Questionnaire-Short Form (Chinese Version) | To investigate impact of the adversities in early life of participants on brain structure and function as well as the interaction effect of childhood adversities and genetic variations,such as 5-HTTLPR polymorphism. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genome-wide association studies, Environmental factors, Behavioral Assessment, Pathway analysis